At Mallinckrodt Pharmaceuticals, we believe equal opportunity and fair treatment should extend to everyone. That is why we prohibit and speak out against any discrimination on the basis of age, color, disability, ethnicity, marital or family status, national origin, race, religion, sex, sexual orientation, gender identity, veteran status, genetic information and any other characteristic protected by law.
Mallinckrodt Teams Up With Girls Inc. on Perfume Design Mentoring Project Supporting STEM Opportunities
President and CEO Mark Trudeau Featured Speaker at the 46th World Economic Forum Annual Meeting in Switzerland
For the first time ever, the Multiple Sclerosis Association of America (MSAA) in collaboration with the Multiple Sclerosis Foundation (MSF) and with support from Mallinckrodt Pharmaceuticals celebrated MS Relapse awareness with the launch of MS Relapse Awareness Week, March 21-25, 2016.
Mallinckrodt joins other BIO member companies in a commitment to investing in, developing, and delivering innovative biopharmaceuticals that positively affect how we treat patients – giving them hope, extending survival, and saving millions of lives – and providing value to patients, caregivers, the healthcare system and our broader world.
A grant provided by Mallinckrodt to North County Incorporated (NCI) is helping make possible the Community Health Access Program (CHAP) for Christian Hospital and SSM Health DePaul Hospital, two important hospitals serving patients in the St. Louis region.